Surrogate antigens as targets for proteome-wide binder selection

Gustavsson, Elin; Ek, Sara; Stéen, Johanna; Kristensson, Malin; Älgenäs, Cajsa; Uhlén, Mathias; Wingren, Christer; Ottosson, Jenny; Hober, Sophia; Borrebaeck, Carl

doi:10.1016/j.nbt.2010.12.005

Cited by 10 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 The specificity of several scFvs antibodies were previously validated using well-characterized, standardized serum samples (with known analytes of the targeted analytes), and orthogonal methods, such as mass spectrometry (affinity pull-down experiments), ELISA, MesoScale Discovery assay, cytometric bead assay, as well as using spike-in and blocking experiments. 19–21,33–38…”

Section: Methodsmentioning

confidence: 99%

Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity

Delfani

Sturfelt

Gullstrand

et al. 2016

Lupus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a severe chronic inflammatory autoimmune connective tissue disease. Despite major efforts, SLE remains a poorly understood disease with unpredictable course, unknown etiology and complex pathogenesis. Apoptosis combined with deficiency in clearing apoptotic cells is an important etiopathogenic event in SLE, which could contribute to the increased load of potential autoantigen(s); however, the lack of disease-specific protein signatures deciphering SLE and the underlying biological processes is striking and represents a key limitation. In this retrospective pilot study, we explored the immune system as a specific sensor for disease, in order to advance our understanding of SLE. To this end, we determined multiplexed serum protein expression profiles of crude SLE serum samples, using antibody microarrays. The aim was to identify differential immunoprofiles, or snapshots of the immune response modulated by the disease, reflecting apoptosis, a key process in the etiology of SLE and disease activity. The results showed that multiplexed panels of SLE-associated serum biomarkers could be decoded, in particular reflecting disease activity, but potentially the apoptosis process as well. While the former biomarkers could display a potential future use for prognosis, the latter biomarkers might help shed further light on the apoptosis process taking place in SLE.

show abstract

Section: Methodsmentioning

confidence: 99%

Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity

Delfani

Sturfelt

Gullstrand

et al. 2016

Lupus

View full text Add to dashboard Cite

show abstract

“…The question should not be whether array-based measurement can work, but how. The solution(s) may lie in developing better binders [7,33], sample fractionation [19], in-solution capture [18], or new and creative modes of dual specificity detection such as the proximity ligation assay [34]. Regardless, we need better standards for assay performance and specificity.…”

Section: Conclusion and Suggestions For Further Progressmentioning

confidence: 99%

Antibody array analysis of labelled proteomes: how should we control specificity?

Holm

Lund-Johansen

2012

New Biotechnology

View full text Add to dashboard Cite

“…The specificity, affinity, and onchip functionality have been assured using stringent phagedisplay screening and selection protocols using different sample formats ranging from pure proteins, mixtures of pure proteins to crude samples (Soderlind et al, 2000). In addition, the specificity of selected antibodies has been validated using pure proteins, mixtures of pure proteins, as well as wellcharacterized, standardized serum samples i) with known levels of the targeted analyte(s), ii) spiked with known level of specific protein(s), and/or iii) depleted of the targeted protein(s), and/or orthogonal methods such as mass spectrometry (affinity pull-down experiments), ELISA, Meso Scale Discovery assay and cytometric bead assay, as well as spiking and blocking experiments ( Supplementary Table 1) (Carlsson et al, 2011b;Dexlin-Mellby et al, 2010;Gustavsson et al, 2011;Ingvarsson et al, 2007Ingvarsson et al, , 2008Kristensson et al, 2012;Pauly et al, 2013;Wingren et al, 2007). Despite stringent selection and validation protocols, one limitation is the lack of information on fine specificity concerning proteoforms, translational modifications and potential complex formations.…”

Section: Generation Of Antibody Microarraysmentioning

confidence: 99%

Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis

et al. 2016

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a disease where detection preceding clinical symptoms significantly increases the life expectancy of patients. In this study, a recombinant antibody microarray platform was used to analyze 213 Chinese plasma samples from PDAC patients and normal control (NC) individuals. The cohort was stratified according to disease stage, i.e. resectable disease (stage I/II), locally advanced (stage III) and metastatic disease (stage IV). Support vector machine analysis showed that all PDAC stages could be discriminated from controls and that the accuracy increased with disease progression, from stage I to IV. Patients with stage I/II PDAC could be discriminated from NC with high accuracy based on a plasma protein signature, indicating a possibility for early diagnosis and increased detection rate of surgically resectable tumors.

show abstract

Surrogate antigens as targets for proteome-wide binder selection

Cited by 10 publications

References 30 publications

Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity

Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity

Antibody array analysis of labelled proteomes: how should we control specificity?

Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis

Contact Info

Product

Resources

About